001     284359
005     20260130151313.0
024 7 _ |a 10.1007/s00702-025-03062-3
|2 doi
024 7 _ |a pmid:41222710
|2 pmid
024 7 _ |a 0375-9245
|2 ISSN
024 7 _ |a 0022-3026
|2 ISSN
024 7 _ |a 0300-9564
|2 ISSN
024 7 _ |a 1435-1463
|2 ISSN
037 _ _ |a DZNE-2026-00127
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Falkenburger, Björn
|0 P:(DE-2719)2814178
|b 0
|u dzne
245 _ _ |a Clinical utility of digital technologies in Parkinson's disease.
260 _ _ |a Wien [u.a.]
|c 2026
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1769782055_7436
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Digital health technologies (DHTs) are on the verge of changing treatment of Parkinson's disease (PD). This narrative overview article describes DHTs that are already used or in development, focusing on technologies available in Germany and on their clinical utility. Examples include applications that are primarily used by patients, i.e., tools for patient education and empowerment, but also stand-alone interventions improving clinical outcomes including motor and non-motor symptoms. In Germany, these patient-centered DHTs fall under the HTA framework of digital health applications (DIGA). DHT for telemonitoring, in contrast, are designed to support physicians and other healthcare providers and therefore medical devices. DHT are also used increasingly as exploratory endpoints in trials testing neuroprotective treatments.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Parkinson Disease: therapy
|2 MeSH
650 _ 2 |a Digital Technology
|2 MeSH
650 _ 2 |a Telemedicine
|2 MeSH
650 _ 2 |a Germany
|2 MeSH
700 1 _ |a Fanciulli, Alessandra
|0 0000-0002-2854-4179
|b 1
700 1 _ |a Pötter-Nerger, Monika
|0 0000-0001-7680-2147
|b 2
700 1 _ |a Eimeren, Thilo
|0 P:(DE-2719)2812285
|b 3
|u dzne
700 1 _ |a Classen, Joseph
|0 0000-0001-7182-6967
|b 4
700 1 _ |a Höglinger, Günter
|0 P:(DE-2719)2811373
|b 5
700 1 _ |a Redecker, Christoph
|0 0000-0001-7452-0525
|b 6
700 1 _ |a Winkler, Jürgen
|b 7
700 1 _ |a Klucken, Jochen
|0 0000-0001-6645-9437
|b 8
773 _ _ |a 10.1007/s00702-025-03062-3
|g Vol. 133, no. 2, p. 297 - 307
|0 PERI:(DE-600)1481655-6
|n 2
|p 297 - 307
|t Journal of neural transmission
|v 133
|y 2026
|x 0375-9245
856 4 _ |u https://pub.dzne.de/record/284359/files/DZNE-2026-00127.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/284359/files/DZNE-2026-00127.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 0
|6 P:(DE-2719)2814178
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 3
|6 P:(DE-2719)2812285
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2811373
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2025-01-02
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2025-01-02
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-02
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NEURAL TRANSM : 2022
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-02
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-02
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-02
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2025-01-02
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21